Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00517075 · ClinicalTrials.gov registry record · Phase 2
Treatment of Negative Symptoms of Schizophrenia With Transcranial Magnetic Stimulation (TMS)
A Phase 2 study, sponsored by New York State Psychiatric Institute.
- Terminated
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
NCT00517075: Clinical Trial Phase 2 study, sponsored by New York State Psychiatric Institute.
NCT00517075 is a Phase 2 study that was terminated before completion, run by New York State Psychiatric Institute. The registered enrollment target is 14 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00517075, a Phase 2 study, was terminated before completion, sponsored by New York State Psychiatric Institute.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
Study Summary
This study will test whether repetitive transcranial magnetic stimulation (rTMS) is helpful in treating negative symptoms and social deficits of schizophrenia. This will be the first rTMS study to assess social function and social cognition. 1. Hypoactivity in the dorsolateral prefrontal cortex (DLPFC) has been implicated in generating the negative symptoms of schizophrenia. Abnormalities in the left inferior parietal lobe (IPL) have also been associated with negative symptoms. We hypothesize that high frequency rTMS applied to the hypoactive left DLPFC or to the left IPL in individuals with schizophrenia will reduce negative symptom severity more than sham (placebo) rTMS as assessed by the Positive and Negative Syndrome Scale (PANSS) negative symptoms subscale. 2. We hypothesize that high frequency rTMS applied to the left DLPFC or to the left IPL in schizophrenia patients will improve social dysfunction more than sham (placebo) rTMS as assessed by the Social Adjustment Scale, the Social Adaptation Self-Evaluation Scale and the Social Functioning Scale.
Interventions
- DEVICE Transcranial Magnetic Stimulation (TMS)
- DEVICE repetitive transcranial magnetic stimulation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2004-09 |
| Est. Completion | 2011-06 |
| Phase | Phase 2 |
Why NCT00517075 stopped before completion
NCT00517075 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 2 interventions - of which Transcranial Magnetic Stimulation (TMS) is the first listed.
NCT00517075 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00517075 about?
NCT00517075 is a clinical study titled "Treatment of Negative Symptoms of Schizophrenia With Transcranial Magnetic Stimulation (TMS)". This study will test whether repetitive transcranial magnetic stimulation (rTMS) is helpful in treating negative symptoms and social deficits of schizophrenia. This will be the first rTMS study to assess social function and social cognition. 1. Hypoactivity in the dorsolateral prefrontal cortex (DL...
What is the current status of trial NCT00517075?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2004-09. Estimated completion is 2011-06.
What interventions are being tested in trial NCT00517075?
The interventions under investigation include: Transcranial Magnetic Stimulation (TMS) (DEVICE), repetitive transcranial magnetic stimulation (DEVICE).
Who is sponsoring clinical trial NCT00517075?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00517075's enrollment target sits among peer trials
14 1941st of 2000 higher than 54 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia